Health authorities in Canada have now approved a so-called fast-track phase 2 study to investigate whether the ingredients in Hofseth BioCare's salmon oil will have a positive effect in treatment.
The goal is to find evidence that compounds in the company's salmon oil can shorten COVID-19 patients' time in the intensive care unit and reduce the number of patients needing respiratory care.
Recruitment of 100 patients to the study will begin immediately, and it is expected that preliminary data from the study will be available in approximately 8-12 weeks. The selection will be made among former smokers and steroid-resistant asthmatics.
These are patient groups that are particularly prone to severe symptoms associated with COVID-19. The study will be conducted in collaboration with the Canadian research institute KGK Science in collaboration with the Mount Sinai Hospital in Toronto.
“The COVID-19 pandemic will continue with great force, and it is very important to work quickly to develop life-saving treatment methods for COVID-19 patients. We are pleased that we have received our approval for our study so quickly, so that we can get started,” says Head of Investor Relations and Strategy, James Berger.
Parts of the population will receive standard treatment, while the other participants in the trial will receive Hofseth BioCare's OmeGo® CARDIO softgel capsules containing pure, natural salmon oil.
“For us it is very motivating to work with reputable research institutions like KGK Science and Mount Sinai Hospital, Toronto. The goal of the study is to document the clinical effect of unique compounds in our salmon oil, ”says Mr. Berger.